Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TBPH 
Theravance Biopharma Inc (TBPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: TBPH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -14.94% | Avg. Invested days 48 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 446.22M USD | Price to earnings Ratio - | 1Y Target Price 14.5 |
Price to earnings Ratio - | 1Y Target Price 14.5 | ||
Volume (30-day avg) 272780 | Beta 0.15 | 52 Weeks Range 7.44 - 10.90 | Updated Date 04/1/2025 |
52 Weeks Range 7.44 - 10.90 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.15 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -87.63% | Operating Margin (TTM) -49.06% |
Management Effectiveness
Return on Assets (TTM) -7.21% | Return on Equity (TTM) -29.04% |
Valuation
Trailing PE - | Forward PE 39.22 | Enterprise Value 407695235 | Price to Sales(TTM) 6.93 |
Enterprise Value 407695235 | Price to Sales(TTM) 6.93 | ||
Enterprise Value to Revenue 6.33 | Enterprise Value to EBITDA -9.69 | Shares Outstanding 49470600 | Shares Floating 21119514 |
Shares Outstanding 49470600 | Shares Floating 21119514 | ||
Percent Insiders 6.22 | Percent Institutions 92.73 |
Analyst Ratings
Rating 3.6 | Target Price 13.2 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Theravance Biopharma Inc
Company Overview
History and Background
Theravance Biopharma, Inc. was founded in 2014 as a spin-off from Theravance, Inc. to focus on discovering, developing, and commercializing organ-selective medicines. It has evolved to focus on gastrointestinal and immunology.
Core Business Areas
- Gastrointestinal Diseases: Development and commercialization of innovative medicines for gastrointestinal (GI) diseases, including IZERVAY.
- Immunology: Development of pipeline assets targeting immunology-related disorders.
Leadership and Structure
Rick E Winningham is the CEO. The organizational structure includes research and development, commercial operations, and corporate functions. The company has a board of directors overseeing its operations.
Top Products and Market Share
Key Offerings
- IZERVAY (avacincaptad pegol): Approved for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Market share is nascent as it is newly launched; key competitors include Apellis Pharmaceuticals' Syfovre. Revenue is expected to grow significantly in the coming years.
- Vibegron: Developed in collaboration with Kissei Pharmaceutical Co., Ltd. is a beta3-adrenergic receptor agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. Theravance receives royalties from sales of vibegron by Kissei in Japan and by Urovant Sciences in the United States. The main competitor is Myrbetriq (mirabegron) marketed by Astellas.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. There is growing demand for novel therapies to address unmet medical needs, particularly in areas like immunology and GI disorders.
Positioning
Theravance Biopharma is positioned as a specialty pharmaceutical company focused on organ-selective medicines, giving it a competitive edge in focused therapeutic areas.
Total Addressable Market (TAM)
The total addressable market for Geographic Atrophy treatment is estimated to be in the billions of dollars. Theravance is positioned to capture a significant portion of this market with IZERVAY. Vibegron for OAB represents another large market opportunity.
Upturn SWOT Analysis
Strengths
- Innovative pipeline of organ-selective medicines
- Strong focus on unmet medical needs
- Established partnerships with leading pharmaceutical companies
- Successful FDA approvals
- Expertise in GI and immunology
Weaknesses
- Reliance on partnerships for commercialization
- High R&D expenses
- Competition from larger pharmaceutical companies
- Potential regulatory setbacks
- Dependence on the success of key pipeline assets
Opportunities
- Expansion into new therapeutic areas
- Acquisition of complementary technologies or assets
- Strategic collaborations to accelerate drug development
- Increased adoption of innovative therapies
- Global expansion
Threats
- Patent expirations
- Generic competition
- Changing regulatory landscape
- Economic downturns impacting healthcare spending
- Clinical trial failures
Competitors and Market Share
Key Competitors
- APLS
- ALNY
- REGN
Competitive Landscape
Assessment of Theravance Biopharma's competitive advantages and disadvantages compared to its competitors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Analysis of Theravance Biopharma's revenue and earnings growth over the past years.
Future Projections: Analyst estimates for future revenue, earnings, and growth rates. Based on pipeline potential and market opportunities.
Recent Initiatives: New drug approvals, clinical trial results, strategic partnerships, and acquisitions.
Summary
Theravance Biopharma is a specialty pharmaceutical company with a focus on GI and immunology. Its strength lies in its innovative pipeline and partnerships. A key challenge is competition from larger companies. The company's future depends on successful commercialization of its key assets, especially IZERVAY, and effective management of R&D expenses.
Similar Companies
- APLS
- ALNY
- REGN
- VRX
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Press Releases
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Theravance Biopharma Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2014-05-16 | CEO & Director Mr. Rick E. Winningham M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 97 | Website https://www.theravance.com |
Full time employees 97 | Website https://www.theravance.com | ||
Theravance Biopharma, Inc., a biopharmaceutical company develops, and commercializes of medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.